Become a member to explore this article in full and discover additional content.
Uses include the electroplating of various substrates to achieve durable, high-quality surfaces.
1
Dec 2023
This decision extends the approval of hydrochloric acid in biocide uses until 31 October 2026.
The applicants sought annulment of the Commission decision which led to the removal of chlorpyrifos-methyl from the EU market.
The investigation delved into the impact of 63 different additives, including plasticisers, heat stabilisers, and flame retardants.
30
Nov 2023
Several importers, manufacturers and users can continue to use MOCA under stringent authorisation conditions.
27
Systemic insecticides, known for their application directly to plants, soil, or as seed treatments, are at the centre of a crucial debate.
Non-renewal of active Thiacloprid prompts updates to Maximum Residue Levels in various products.
“LONG LIVE THE BEE” foundation challenges the renewal of the controversial chemical.
Consultations on harmonised classification and labelling, new intentions and proposals to harmonise classification and labelling.
The Commission cites challenges and delays encountered in the process.
An EU-wide enforcement project found about 60 active substances in biocidal products that are banned.
Manufacturers and suppliers can continue to place these products on the market until their new expiration dates.
Authorised uses include cell extraction, chromatographic purification and solvent exchange and more.
Stakeholders have an opportunity to inform the new requirements for these substances.
The fungicide has potential endocrine disrupting properties but non-renewal would have had a significant impact on society.
The substance exhibits endocrine-disrupting properties with potentially adverse effects on humans.
The approval comes with specific conditions on use to protect operators, workers and bystanders.
The Commission's approval comes with specific provisions on use to ensure environmental and worker safety.
Chromium trioxide is suspected of causing cancer but the Commission decides that the benefits of these users far outweigh the risks.
Industry gets more time to make a gradual shift to DEHP-free medical devices.
22
